NIAID-supported investigator Dr. Kelly Henrickson’s team of scientists designed a fast diagnostic test for H1N1. Read the interview with Dr. Henrickson.
Learn how immunizing a critical portion of a community protects most members of the community.
In August 2009, NIAID began a series of clinical trials to evaluate new vaccines to prevent and decrease the severity of H1N1 influenza virus infection. Through the summer and fall, NIAID collected and analyzed information from thousands of volunteers at medical facilities across the country.
Several trials studied how many doses of H1N1 vaccine were needed to induce a potentially protective immune response in a variety of populations, including healthy adults, the elderly, children, pregnant woman, people with asthma, and people with HIV. Other trials sought to measure vaccine safety and immune response of volunteers given the seasonal flu vaccine before, after, or concurrently with the H1N1 vaccine.
The NIAID trials were designed to support public health decisions about vaccination schedules for different groups, including special populations that are not often included in clinical trials for flu vaccines.
These trials are analyzed responses to injected vaccines containing inactivated influenza virus. Vaccines containing live, attenuated virus delivered in a nasal spray were not included in these clinical trials.
Safety data was collected and monitored closely by the study investigators and an independent safety monitoring committee.
back to top
Last Updated November 24, 2010